Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | -1.87 % |
3 Month Return | -0.89 % |
1 Year Return | + 4.85 % |
Market Stats | |
Previous Close | ₹38.01 |
Open | ₹38.00 |
Volume | 14.28K |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹38.01Cr |
P/E Ratio | -74.24 |
PEG Ratio | 31.86 |
Market Cap | ₹38.01 Cr |
P/B Ratio | 1.04 |
EPS | 0.47 |
Dividend Yield | 0 |
Sector | Pharmaceuticals |
ROE | 1.28 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
NA | ₹38.01 Cr | 26.89% | 0.67 | ₹1 Cr | ₹44 Cr | |
NA | ₹214.08 Cr | 213.48% | 0.58 | -₹12 Cr | ₹15 Cr | |
NA | ₹905.32 Cr | 817.04% | 0.65 | ₹23 Cr | ₹307 Cr | |
HOLD | ₹4,202.80 Cr | 27.13% | 0.50 | ₹136 Cr | ₹623 Cr | |
BUY | ₹13,741.09 Cr | 74.1% | 0.63 | ₹405 Cr | ₹4,506 Cr |
Organisation | Concord Drugs Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Retail Holding Up
Retail Investor have increased holdings from 44.59% to 45.61% in Sep 2024 quarter
Price Rise
In the last 7 days, Concord Drugs stock has moved up by 8.2%
Profit Spike
Netprofit is up for the last 3 quarters, -0.34 Cr → 0.04 Cr (in ₹), with an average increase of 629.2% per quarter
Revenue Rich
Revenue is up for the last 2 quarters, 11.69 Cr → 12.37 Cr (in ₹), with an average increase of 5.5% per quarter
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 64.2% return, outperforming this stock by 59.3%
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 142.7% return, outperforming this stock by 114.4%
Promoter Holding Down
Promoters have decreased holdings from 55.41% to 54.39% in Sep 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 54.39% | ||
Foreign Institutions | 0% | 0.00 | |
Mutual Funds | 0% | 0.00 | |
Retail Investors | 45.61% | 2.27 | |
Others | 0% | 0.00 |
Concord Drugs Ltd in the last 5 years
Lowest (-75.65x)
November 7, 2024
Today (-74.24x)
December 6, 2024
Industry (57.44x)
December 6, 2024
Highest (791.40x)
July 3, 2024
Concord Drugs Ltd’s net profit fell -92.86% since last year same period to ₹0.04Cr in the Q2 2024-2025. On a quarterly growth basis, Concord Drugs Ltd has generated 33.33% jump in its net profits since last 3-months.
Read More about Earnings ResultsBearish
Neutral
Bullish
Concord Drugs Ltd is currently in a Bullish trading position according to technical analysis indicators.
Concord Drugs Ltd (538965) share price today is ₹37.65
Concord Drugs Ltd is not listed on NSE
Concord Drugs Ltd is listed on BSE
PE Ratio of Concord Drugs Ltd is -74.24
PE ratio = Concord Drugs Ltd Market price per share / Concord Drugs Ltd Earnings per share
Today’s traded volume of Concord Drugs Ltd(538965) is 14.28K.
Today’s market capitalisation of Concord Drugs Ltd(538965) is ₹38.01Cr.
Concord Drugs Ltd(538965 | Price |
---|---|
52 Week High | ₹61.5 |
52 Week Low | ₹30.59 |
Concord Drugs Ltd(538965) share price is ₹37.65. It is down -38.78% from its 52 Week High price of ₹61.5
Concord Drugs Ltd(538965) share price is ₹37.65. It is up 23.08% from its 52 Week Low price of ₹30.59
Concord Drugs Ltd(538965 | Returns |
---|---|
1 Day Returns | -0.36% |
1 Month Returns | -1.87% |
3 Month Returns | -0.89% |
1 Year Returns | 4.85% |